Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.
Memorial Sloan Kettering Physician-in-Chief José Baselga studies mechanisms of resistance to targeted therapies and identification of novel therapeutic combinations in solid cancers.
Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.
Physician-scientist Cameron Brennan focuses on genomic analysis of human and mouse gliomas and medulloblastomas.
Physician-scientist Timothy Chan focuses on the identification and characterization of tumor suppressors in glioblastoma and breast cancer.
Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
Physician-scientist Yu Chen studies the role of transcription factors that are critical for prostate cancer development.
Physician-scientist Emily Cheng focuses on the molecular mechanisms of cell death and their implications in tumorigenesis and cancer therapy, with primary emphasis on lung and kidney cancers.
Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic transcription factors in GIST and other solid tumors.
Physician-scientist James Fagin focuses on the pathogenesis of thyroid cancer and the role of oncogenic kinases.
Physician-scientist James Hsieh focuses on developing novel therapeutics targeting cancer cell proliferation; he also directs Memorial Sloan Kettering’s translational kidney cancer research program.
Physician-scientist Jason Huse focuses on the molecular pathogenesis of brain tumors, particularly high-grade gliomas.
Physician-scientist Christine Iacobuzio-Donahue studies the genomics and cell biology of pancreatic and other solid tumors as it relates to subclonal evolution, tumor progression, and metastasis.
Molecular pathologist Marc Ladanyi studies the molecular pathogenesis of sarcomas, lung cancer, and mesothelioma.
Physician-scientist Steven Leach studies molecular, genetic, and cellular determinants of pancreatic cancer initiation and progression.
Physician-scientist Ross Levine focuses on the investigation of genetic basis of hematopoietic malignancies.
Physician-scientist Ingo Mellinghoff studies signal transduction alterations in primary brain tumors.
Physician-scientist Christopher Park focuses on the identification and characterization of molecular pathways that regulate normal and malignant stem cells in the hematopoietic system.
Physician-scientist Jorge Reis-Filho focuses on the development of a predictive molecular classification for rare types of breast cancer and characterization of intratumor genetic heterogeneity in breast cancers.
Human Oncology and Pathogenesis Program Chair Charles Sawyers develops molecularly targeted cancer therapy.
Cancer biologist Nikolaus Schultz uses computational tools to study the diversity of genomic alterations underlying different cancer types.
Physician-scientist David Solit studies human oncology and pathogenesis, genomics, oncogenes and tumor suppressors, cancer therapeutics, and clinical trials.
Researcher Barry Taylor focuses on defining the somatic abnormalities that mediate the genesis, progression, and response to therapy of human cancers.